- Home
- NGS vs CLLS Comparison
NGS vs CLLS Comparison
Compare NGS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGS | CLLS |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.3M | 299.0M |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NGS | CLLS |
|---|---|---|
| Price | $32.18 | $4.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $35.67 | $8.00 |
| AVG Volume (30 Days) | 96.5K | ★ 138.2K |
| Earning Date | 11-10-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 14.85 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $166,824,000.00 | $82,551,000.00 |
| Revenue This Year | $9.50 | $32.58 |
| Revenue Next Year | $13.88 | N/A |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | 9.53 | ★ 129.04 |
| 52 Week Low | $16.73 | $1.10 |
| 52 Week High | $32.93 | $5.48 |
Technical Indicators
Market Signals| Indicator | NGS | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 58.54 |
| Support Level | $30.54 | $4.52 |
| Resistance Level | $32.05 | $4.92 |
| Average True Range (ATR) | 1.11 | 0.29 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 77.78 | 56.90 |
Price Performance
Historical ComparisonAbout NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.